Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 10/20 | 1.00 |
| ▸ | ULK1 | O75385 | 1/20 | 0.54 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.47 |
| ▸ | EP300 | Q09472 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.45 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.45 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19710217 | 1.00 | SMYD3 (1.00) | SMYD3ULK1TLK2EP300CREBBP | |
| SCHEMBL17591718 | 0.82 | SMYD3 (1.00) | SMYD3GRIN1GRIN2BGRIN2DGRIN3B | |
| SCHEMBL17591717 | 0.82 | SMYD3 (1.00) | SMYD3GRIN1GRIN2BGRIN2DGRIN3B | |
| SCHEMBL23143564 | 0.81 | SMYD3 (0.68) | SMYD3EP300CREBBPGRIN1GRIN2B | |
| SCHEMBL5728126 | 0.78 | SMYD3 (0.64) | SMYD3TLK2GRIN1GRIN2BGRIN2D | |
| SCHEMBL6744135 | 0.78 | SMYD3 (0.64) | SMYD3 | |
| SCHEMBL27608681 | 0.77 | SMYD3 (0.62) | SMYD3TLK2GRIN1GRIN2BGRIN2D | |
| SCHEMBL578342 | 0.77 | SMYD3 (0.61) | SMYD3TLK2GRIN1GRIN2BGRIN2D | |
| SCHEMBL29642948 | 0.77 | SMYD3 (0.61) | SMYD3TLK2GRIN1GRIN2BGRIN2D | |
| SCHEMBL7297231 | 0.76 | SMYD3 (0.61) | SMYD3ULK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | claimed |
| US-20190322660-A1 | SMYD INHIBITORS | Epizyme, Inc. | 2019-10-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | SMYD3 1/4885ULK1 3803/4885TLK2 2682/4885 |
| US-20190322660-A1 | SMYD INHIBITORS | SMYD2, SMYD3, SMURF2 | SMYD3 2/4885ULK1 3670/4885TLK2 2916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.